Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: A systematic review and meta-analysis

Medicine (United States)

Volumn 95, Issue 3, 2016, Pages

  Yin, Xiaotao ^a   Xiao, Yi ^a   Li, Fanglong ^a   Qi, Siyong ^a   Yin, Zhaoyang ^a   Gao, Jiangping ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; KETOCONAZOLE; SUNITINIB;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; MALE; META ANALYSIS; METASTASIS; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; SYSTEMATIC REVIEW; BLOOD; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MORTALITY; NEUTROPHIL; PROGNOSIS; PROSTATIC NEOPLASMS;

HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NEUTROPHILS; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84971379536     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002544     Document Type: Article

References (44)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
3. Sonpavde G, Attard G, Bellmunt J, et al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol. 2011;60:270-278.
4. Beltran H, Beer TM, Carducci MA, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60:279-290.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-1197.
7. Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008;112:69-74.
8. Svatek R, Karakiewicz PI, Shulman M, et al. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy- naive androgen independent prostate cancer. Eur Urol. 2006;49:666-674.
9. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
12. Templeton AJ, Pezaro C, Omlin A, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346-3352.
13. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.
14. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009;339:b2535.
15. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc. 2000;283:2008-2012.
16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557-560.
17. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
18. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Br MedJ. 1997;315:629-634.
19. Yao A, Sejima T, Iwamoto H, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castrationresistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015;22:827-833.
20. Sonpavde G, Pond GR, Armstrong AJ, et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castrationresistant prostate cancer. Clin Genitourin Cancer. 2014;12:317-324.
21. Sharma V, Cockerill PA, Viers BR, et al. The association of preoperative neutrophil to lymphocyte ratio with oncologic outcomes following radical prostatectomy for prostate cancer. J Urol. 2015;193:e55-e56.
22. Poyet C, Adank JP, Keller E, et al. Pretreatment systemic inflamatory response parameters do not predict the outcome in men with prostate cancer undergoing radical prostatectomy. J Urol. 2015;193:e817.
23. Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. Br J Urol Int. 2014;114:E11-E17.
24. Minardi D, Scartozzi M, Montesi L, et al. Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. Springerplus. 2015;4:255.
25. McLachlan JM, Chan DL, Crumbaker MA, et al. Neutrophil- lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer. Cancer Treat Commun. 2015;4:81-85.
26. Lorente D, Mateo J, Templeton AJ, et al. Baseline neutrophillymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26: 750-755.
27. Linton A, Pond G, Clarke S, et al. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 2013;11:423-430.
28. Langsenlehner T, Thurner EM, Krenn-Pilko S, et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol. 2015;33: 1661-1667.
29. Keizman D, Gottfried M, Ish-Shalom M, et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012;17: 1508-1514.
30. Templeton AJ, Omlin AG, Pezaro CJ, et al. A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy. J Clin Oncol. 2014;32(4 Suppl):70.
31. Nakagami Y, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel risk stratification model in castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Urol. 2015;193:e1084.
32. Hernandez DJ, Nielsen ME, Han M, et al. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology. 2007;70:931-935.
33. Hu K, Lou L, Ye J, et al. Prognostic role of the neutrophillymphocyte ratio in renal cell carcinoma: a meta-analysis. Br Med J Open. 2015;5:e006404.
34. Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-tolymphocyte ratio in colorectal cancer: a systematic review and metaanalysis. Int J Cancer. 2014;134:2403-2413.
35. Cedres S, Torrejon D, Martinez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14:864-869.
36. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A. 1989;86:9499-9503.
37. An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15:516-522.
38. Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120:1151-1164.
39. Hofman PM. Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol. 2010;16:5790-5800.
40. Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284:1-5.
41. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93-103.
42. Nind AP, Nairn RC, Rolland JM, et al. Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973;28:108-117.
43. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134:230-234.
44. Xu Q, Chen Y-J, Liu Z-Q, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014;16:467.